Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Pharma-Bio Serv (PBSV) Liabilities and Shareholders Equity (2016 - 2026)

Pharma-Bio Serv (PBSV) has disclosed Liabilities and Shareholders Equity for 15 consecutive years, with $13.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Liabilities and Shareholders Equity fell 16.2% year-over-year to $13.7 million, compared with a TTM value of $57.2 million through Oct 2025, down 16.79%, and an annual FY2025 reading of $13.7 million, down 16.2% over the prior year.
  • Liabilities and Shareholders Equity was $13.7 million for Q4 2025 at Pharma-Bio Serv, roughly flat from $13.6 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $30.2 million in Q1 2021 and bottomed at $13.6 million in Q3 2025.
  • Average Liabilities and Shareholders Equity over 5 years is $20.1 million, with a median of $20.0 million recorded in 2022.
  • The sharpest move saw Liabilities and Shareholders Equity rose 15.44% in 2021, then fell 28.91% in 2022.
  • Year by year, Liabilities and Shareholders Equity stood at $23.9 million in 2021, then dropped by 13.67% to $20.7 million in 2022, then decreased by 3.63% to $19.9 million in 2023, then dropped by 18.14% to $16.3 million in 2024, then fell by 16.2% to $13.7 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for PBSV at $13.7 million in Q4 2025, $13.6 million in Q3 2025, and $13.9 million in Q2 2025.